These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34088448)

  • 1. Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study.
    Mulet X; Fernández-Esgueva M; Norte C; Zamorano L; Del Barrio-Tofiño E; Oliver A;
    Enferm Infecc Microbiol Clin (Engl Ed); 2021; 39(6):279-282. PubMed ID: 34088448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones.
    Mulet X; García R; Gayá M; Oliver A
    Eur J Clin Microbiol Infect Dis; 2019 Mar; 38(3):541-544. PubMed ID: 30680561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.
    Del Barrio-Tofiño E; Zamorano L; Cortes-Lara S; López-Causapé C; Sánchez-Diener I; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    J Antimicrob Chemother; 2019 Jul; 74(7):1825-1835. PubMed ID: 30989186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.
    Pérez A; Gato E; Pérez-Llarena J; Fernández-Cuenca F; Gude MJ; Oviaño M; Pachón ME; Garnacho J; González V; Pascual Á; Cisneros JM; Bou G
    J Antimicrob Chemother; 2019 May; 74(5):1244-1252. PubMed ID: 30753505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.
    Del Barrio-Tofiño E; Sánchez-Diener I; Zamorano L; Cortes-Lara S; López-Causapé C; Cabot G; Bou G; Martínez-Martínez L; Oliver A;
    J Antimicrob Chemother; 2019 Nov; 74(11):3217-3220. PubMed ID: 31430372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals.
    García-Castillo M; Del Campo R; Morosini MI; Riera E; Cabot G; Willems R; van Mansfeld R; Oliver A; Cantón R
    J Clin Microbiol; 2011 Aug; 49(8):2905-10. PubMed ID: 21697331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    J Antimicrob Chemother; 2017 Nov; 72(11):3079-3084. PubMed ID: 28961968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS.
    Hernández-García M; García-Castillo M; García-Fernández S; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Romano J; Pássaro L; Paixão L; López-Mendoza D; Díaz-Regañón J; Cantón R;
    J Antimicrob Chemother; 2021 Jan; 76(2):370-379. PubMed ID: 33099623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones.
    Gomis-Font MA; Cabot G; López-Argüello S; Zamorano L; Juan C; Moyá B; Oliver A
    J Antimicrob Chemother; 2022 Mar; 77(4):957-968. PubMed ID: 35084040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.
    Cabot G; Ocampo-Sosa AA; Domínguez MA; Gago JF; Juan C; Tubau F; Rodríguez C; Moyà B; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6349-57. PubMed ID: 23045355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome sequence-guided PCR for the rapid identification of the Pseudomonas aeruginosa ST175 high-risk clone directly from clinical samples.
    Cabot G; Lara-Esbrí P; Mulet X; Oliver A
    J Antimicrob Chemother; 2021 Mar; 76(4):945-949. PubMed ID: 33351893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying bla
    PÉrez-VÁzquez M; Sola-Campoy PJ; Zurita ÁM; Ávila A; GÓmez-Bertomeu F; SolÍs S; LÓpez-Urrutia L; GÓnzalez-BarberÁ EM; Cercenado E; Bautista V; Lara N; Aracil B; Oliver A; Campos J; Oteo-Iglesias J;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106026. PubMed ID: 32450200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.